The economic recession has not inhibited the growth of FDA approved antibody drugs and the market for these drugs. So far treatments for Cancer, Arthritis, Autoimmune diseases and Transplant rejection have dominated the class of drugs derived from monoclonal antibodies. The future products will include additional drugs for treatment of the above diseases and others such as Osteoporosis and Asthma.
Monoclonal antibody derived therapeutics have become a significant part of the overall drug market boasting over $40 billion in sales as of 2010 and is likely to double in the next ten years. The development of monoclonal antibodies continues to grow and clearly, faster ready-to-use kits to help rapid determination of the IgG levels in such antibodies remain important tools in the drug discovery and development process.
All major pharmaceutical and biotech companies have active programs in developing monoclonal antibodies. Smaller biotech companies focus on developing such antibodies only, whereas universities and research institutions utilize grants to discover new targets with monoclonal antibody technologies.
ADMEcell and RD-Biotech (Besancon, France) offer a new line of Ready-To-Use 30 minute assay kits to quantitate Human, Mouse, Rat and Bovine IgG in cell culture supernatant, ascites and serum-all assays covering a wide dynamic range (i.e. 16-1000ng/ml for human IgG). Color coded buffer solutions simplify the pipetting steps. Recombinant or fully humanized monoclonal antibodies can be assayed. Also included in the product line is the Mouse IGg sotyping kit.